UPDATED: Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Coming up behind the other major PD-1 players, Regeneron sought to create its own market for Libtayo by going into indications where others have yet to venture — a strategy CSO George Yancopoulos likes to boast about. Now, the drug can directly compete against the heavyweights with its third approval.
The FDA gave Libtayo the green light as a monotherapy for advanced non-small cell lung cancer in the first-line setting, the same indication that made Merck’s Keytruda one of the most successful franchises in pharma. But it hasn’t been easy going for every drug: Bristol Myers Squibb’s Opdivo suffered one of its worst flops in NSCLC almost four and a half years ago.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.